Has Dennis Moore, MD received payments from drug or device companies?

Yes. Drug and device makers reported $25,618 in general payments to Dennis Moore, MD across 967 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dennis Moore, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dennis Moore, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dennis Moore, MD

Hematology & Oncology · Wichita, KSNPI 1043272305

Payments from drug & device makers

$25,618in general payments, 2019–2025

Across 967 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$2K
Gilead$2K
AstraZeneca$1K
E.r. Squibb & Sons, L.L.C.$1K
Rigel Pharmaceuticals, Inc.$1K
Dova Pharmaceuticals$993
plus $17K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	32	$2,040
Gilead(2 entities)	28	$1,759
AstraZeneca(2 entities)	36	$1,239
E.r. Squibb & Sons, L.L.C.	75	$1,141
Rigel Pharmaceuticals, Inc.	11	$1,013
Dova Pharmaceuticals	2	$993
Novartis	68	$949
Astellas Pharma US Inc	33	$919
Merck	48	$916
Bristol Myers Squibb	49	$881
Eagle Pharmaceuticals, Inc.	1	$850
Karyopharm Therapeutics Inc.	6	$846
Genentech USA, Inc.	45	$770
AbbVie	44	$705
Seagen Inc.	32	$657
GSK	41	$653
Pfizer	42	$597
Myriad Genetic Laboratories, Inc.	8	$556
Daiichi Sankyo Inc.	19	$501
Johnson & Johnson	20	$494
Amgen	27	$443
AVEO Pharmaceuticals, Inc.	11	$434
Eisai Inc.	14	$355
Takeda Pharmaceuticals U.S.A., Inc.	16	$354
Athenex Pharmaceutical Division, LLC	2	$350
Puma Biotechnology, Inc.	10	$341
Epizyme, Inc.	10	$265
Pharmacyclics LLC, An Abbvie Company	16	$254
Exelixis Inc.	14	$244
EMD Serono, Inc.	14	$218
Lilly USA, LLC	9	$214
Novocure GmbH	1	$200
Incyte Corporation	6	$193
Sobi, Inc	6	$174
Jazz Pharmaceuticals Inc.	7	$147
Blueprint Medicines Corporation	9	$140
Stemline Therapeutics Inc.	8	$139
Tersera Therapeutics LLC	7	$133
Beigene USA, Inc.	9	$121
Intuitive Surgical	1	$118
Clovis Oncology, Inc.	4	$117
Bayer	7	$112
Sun Pharmaceutical Industries Inc.	7	$110
Regeneron Healthcare Solutions, Inc.	6	$105
Adaptive Biotechnologies Corporation	4	$97
Ipsen Biopharmaceuticals, Inc	6	$84
Apellis Pharmaceuticals, Inc.	4	$82
Recordati_rare_diseases_inc.	4	$75
Boehringer Ingelheim	4	$73
ADC Therapeutics America, Inc.	4	$71
Pharmaessentia USA Corporation	4	$69
Octapharma USA, Inc.	4	$69
Servier Pharmaceuticals LLC	4	$66
Springworks Therapeutics, Inc.	4	$61
Taiho Oncology, Inc.	4	$59
Avyxa Pharma, LLC	3	$56
Array Biopharma Inc	3	$53
CTI Biopharma Corp.	3	$53
Coherus Oncology, Inc.	3	$51
Deciphera Pharmaceuticals Inc.	2	$47

How this compares

$25,618 in reported general payments places this provider in the 60th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas →

Medicare billing

Part B allowed, 2024

$12,157,304

Medicare patients

1,713

Services billed

533,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Wichita

Shaker DakhilWichita$11.2M
Bassam MattarWichita$1.9M
Quoc TruongWichita$539K
Christopher DakhilWichita$114K
Phu TruongWichita$73K
Pavan ReddyWichita$69K
Nassim NabboutWichita$29K
Jeremy DeutschWichita$28K
Seth PageWichita$19K
Priyanka SharmaWestwood$18.5M

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →